First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. - Heymach JV; Yamamoto N; Girard N; Ruiter G; Smit EF; Planchard D; Nadal E; Wu YL; Zugazagoitia J; Tu HY; Baik CS; Yoh K; et al. (The New England journal of medicine, 2026)